Radioiodinated N-(alkylaminoalkyl)-substituted 4-methoxy-, 4-hydroxy-, and 4-aminobenzamides: biological investigations for the improvement of melanoma-imaging agents.

doi:10.1016/S0969-8051(97)80002-9

Paper

DOI: 10.1016/S0969-8051(97)80002-9

Radioiodinated N-(alkylaminoalkyl)-substituted 4-methoxy-, 4-hydroxy-, and 4-aminobenzamides: biological investigations for the improvement of melanoma-imaging agents.

Published Jul 1, 1997 · A. Mohammed, C. Nicholl, U. Titsch

Nuclear medicine and biology

Q2 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

Radioiodinated 4-methoxy benzamide derivatives show superior melanoma uptake and excellent melanoma/non-target-tissue ratios, making them ideal for melanoma imaging.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/0969-8051(95)00020-X

Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents.

BZA derivatives show promising potential for early-stage melanoma imaging, with promising tumor targeting and blood clearance rates.

1995·38citations·M. Moreau et al.·Nuclear medicine and biology

Nuclear medicine and biology

DOI:

A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide.

[125I]PAB shows high affinity for human malignant melanoma cells and shows promising biodistribution in mice, with potential as an external marker for malignant melanoma.

1993·103citations·C. John et al.·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

DOI:

Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).

Iodine-123-BZA scintigraphy is a safe and useful agent for detecting and monitoring malignant melanoma patients, allowing for detection of unsuspected lesions and evaluation of therapeutic results.

1993·128citations·J. Michelot et al.·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

DOI: 10.1016/0969-8051(93)90083-7

Synthesis and biological evaluation of radioiodinated N-2-(4-piperidyl)ethyl benzamides.

Compounds 5-7 exhibit nanomolar affinity for the sigma binding site, suggesting potential as anticholinesterase agents with reduced potency.

1993·5citations·S. Efange et al.·Nuclear medicine and biology

Nuclear medicine and biology

DOI:

Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma.

N-(2-diethylaminoethyl)-4-iodobenzamide shows the highest melanoma uptake and potential for external detection of melanoma, with high tumor/nontumor ratios compared to iodoamphetamine.

1991·91citations·Josette M. Michelot et al.·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Citations

DOI: 10.3390/pharmaceutics15061733

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Targeted radionuclide therapy, using innovative targeting agents and radioisotopes, has advanced to provide more effective, safer, and personalized cancer treatments.

2023·21citations·N. Lepareur et al.·Pharmaceutics

Pharmaceutics

DOI: 10.1002/adtp.201800122

Polymer Nanoplatforms at Work in Prostate Cancer Therapy

Polymer nanoplatforms show promise in prostate cancer therapy due to their well-controlled release profiles and improved tumor targeting abilities.

2019·16citations·Liang He et al.·Advanced Therapeutics

Advanced Therapeutics

DOI: 10.1002/adma.201603451

Targeting Nanocarriers with Anisamide: Fact or Artifact?

Anisamide's tumor-targeting effect on nanocarriers varies among studies, questioning its utility in cancer treatment.

2017·32citations·Athanasia Dasargyri et al.·Advanced Materials

Advanced Materials

DOI: 10.1002/cbdv.201400208

Free‐Radical‐Scavenging, Antityrosinase, and Cellular Melanogenesis Inhibitory Activities of Synthetic Isoflavones

Synthetic isoflavones retusin (17) and texasin (20) show potent free-radical-scavenging capacities and efficient inhibition of cellular melanogenesis, suggesting potential for advanced cosmeceutical development.

2015·20citations·Tzy-Ming Lu et al.·Chemistry & Biodiversity

Chemistry & Biodiversity

DOI: 10.1016/j.ejmech.2012.02.014

99mTc(I)/Re(I) tricarbonyl complexes for in vivo targeting of melanotic melanoma: Synthesis and biological evaluation.

99mTc(I) tricarbonyl complexes Tc1 and Tc4 show promising in vivo targeting of melanotic melanoma, with Tc1 showing moderate tumor uptake and favorable target/non-target ratios.

2012·13citations·C. Moura et al.·European journal of medicinal chemistry

European journal of medicinal chemistry